Literature DB >> 33546494

What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report.

Morgane Guillou-Landreat1,2,3, Antoine Dany2, Gaëlle Challet-Bouju1,4, Edouard Laforgue1,4, Juliette Leboucher4, Jean Benoit Hardouin1, Caroline Victorri-Vigneau1,5, Marie Grall-Bronnec1,3,4.   

Abstract

(1) Background: Opioid use disorder (OUD) is a complex condition that can require long-term treatment. Pharmacological therapy for OUD involves treatment with opioid agonists (OMT) tailored to individual profiles. The aim of our study in daily clinical practice was to compare the profiles of patients treated with methadone (MTD) and those using buprenorphine (BHD or BHD-naloxone-NX). (2)
Methods: A cross-sectional multicentre study explored the psychological, somatic and social profiles of patients with Opioid Use Disorder (OUD) following Opioid Maintenance Treatment (BHD, BHD/NX, or MTD). Descriptive and comparative analyses were performed. (3)
Results: 257 patients were included, a majority were men using heroin. A total of 68% (178) were on MTD, 32% (79) were on BHD. Patients with MTD were significantly more likely to report somatic damage, and more likely to be younger and not to report oral or sublingual use as the main route for heroin or non-medical opioids. (4) Conclusions: In daily clinical practice, somatic damage was significantly more severe among MTD patients. Age and route of administration also differed, and our results could raise the issue of the type of OMT prescribed in case of non-medical use of prescribed opioids. These hypothesis should be confirmed in larger studies.

Entities:  

Keywords:  buprenorphine; daily clinical practice; methadone; opiate medication treatment

Year:  2021        PMID: 33546494      PMCID: PMC7913704          DOI: 10.3390/ijerph18041425

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  12 in total

Review 1.  [Therapeutic strategies for opioid addiction: the role of substitution therapy].

Authors: 
Journal:  Presse Med       Date:  2004-10-23       Impact factor: 1.228

2.  [Validation of a questionnaire to screen for harmful use of alcohol and cannabis in the general population: CRAFFT-ADOSPA].

Authors:  Laurent Karila; Stéphane Legleye; François Beck; Emmanuelle Corruble; Bruno Falissard; Michel Reynaud
Journal:  Presse Med       Date:  2007-02-02       Impact factor: 1.228

Review 3.  Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus.

Authors:  Maurice Dematteis; Marc Auriacombe; Oscar D'Agnone; Lorenzo Somaini; Néstor Szerman; Richard Littlewood; Farrukh Alam; Hannu Alho; Amine Benyamina; Julio Bobes; Jean Pierre Daulouede; Claudio Leonardi; Icro Maremmani; Marta Torrens; Stephan Walcher; Michael Soyka
Journal:  Expert Opin Pharmacother       Date:  2017-12-03       Impact factor: 3.889

4.  The Lie/Bet Questionnaire for screening pathological gamblers.

Authors:  E E Johnson; R Hamer; R M Nora; B Tan; N Eisenstein; C Engelhart
Journal:  Psychol Rep       Date:  1997-02

Review 5.  DSM-5 criteria for substance use disorders: recommendations and rationale.

Authors:  Deborah S Hasin; Charles P O'Brien; Marc Auriacombe; Guilherme Borges; Kathleen Bucholz; Alan Budney; Wilson M Compton; Thomas Crowley; Walter Ling; Nancy M Petry; Marc Schuckit; Bridget F Grant
Journal:  Am J Psychiatry       Date:  2013-08       Impact factor: 18.112

6.  Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study.

Authors:  Caroline Victorri-Vigneau; Céline Verstuyft; Régis Bouquié; Edouard-Jules Laforgue; Jean-Benoit Hardouin; Juliette Leboucher; Bertrand Le Geay; Corine Dano; Gaëlle Challet-Bouju; Marie Grall-Bronnec
Journal:  Br J Clin Pharmacol       Date:  2019-05-11       Impact factor: 4.335

7.  Risk of adverse health outcomes with increasing duration and regularity of opioid therapy.

Authors:  Leonard J Paulozzi; Kun Zhang; Christopher M Jones; Karin A Mack
Journal:  J Am Board Fam Med       Date:  2014 May-Jun       Impact factor: 2.657

8.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

Authors:  T F Heatherton; L T Kozlowski; R C Frecker; K O Fagerström
Journal:  Br J Addict       Date:  1991-09

Review 9.  Why buprenorphine is so successful in treating opiate addiction in France.

Authors:  M Fatseas; Marc Auriacombe
Journal:  Curr Psychiatry Rep       Date:  2007-10       Impact factor: 5.285

Review 10.  What we have learned from the Methadone Maintenance Treatment of Dual Disorder Heroin Use Disorder patients.

Authors:  Angelo G I Maremmani; Matteo Pacini; Icro Maremmani
Journal:  Int J Environ Res Public Health       Date:  2019-02-03       Impact factor: 3.390

View more
  1 in total

1.  Mortality in homeless people enrolled in the French housing first randomized controlled trial: a secondary outcome analysis of predictors and causes of death.

Authors:  Aurélie Tinland; Sandrine Loubiere; Matthieu Cantiello; Mohamed Boucekine; Vincent Girard; Owen Taylor; Pascal Auquier
Journal:  BMC Public Health       Date:  2021-07-02       Impact factor: 3.295

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.